P1.21-06 Extracellular Vesicles and Radiomics Predict Durable Response to Immune-Checkpoint Inhibitors in Patients with Non-small Cell Lung Cancer.

MLA

de Miguel Perez, D., et al. “P1.21-06 Extracellular Vesicles and Radiomics Predict Durable Response to Immune-Checkpoint Inhibitors in Patients with Non-Small Cell Lung Cancer.” Journal of Thoracic Oncology, vol. 18, no. 11, Nov. 2023, p. S236. EBSCOhost, https://doi.org/10.1016/j.jtho.2023.09.392.

APA

de Miguel Perez, D., Mamindla, P., Russo, A., Ak, M., Gunasekaran, M., Del Re, M., Buemi, F., Hirsch, F. R., Cardona, A. F., Arrieta, O., Naing, A., Kaushal, S., Adamo, V., Colen, R., & Rolfo, C. (2023). P1.21-06 Extracellular Vesicles and Radiomics Predict Durable Response to Immune-Checkpoint Inhibitors in Patients with Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 18(11), S236. https://doi.org/10.1016/j.jtho.2023.09.392

Chicago

de Miguel Perez, D., P. Mamindla, A. Russo, M. Ak, M. Gunasekaran, M. Del Re, F. Buemi, et al. 2023. “P1.21-06 Extracellular Vesicles and Radiomics Predict Durable Response to Immune-Checkpoint Inhibitors in Patients with Non-Small Cell Lung Cancer.” Journal of Thoracic Oncology 18 (11): S236. doi:10.1016/j.jtho.2023.09.392.